Actively Recruiting
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Led by Step Pharma, SAS · Updated on 2026-04-23
180
Participants Needed
15
Research Sites
225 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
CONDITIONS
Official Title
A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent and able to follow study procedures
- Male or female aged 18 years or older
- Diagnosed with B-cell or T-cell lymphoma that has relapsed or is refractory
- Have received at least two prior systemic therapies with no known beneficial treatment options
- Have measurable disease according to lymphoma classification guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Life expectancy greater than 3 months
- Adequate bone marrow, liver, kidney, and blood clotting function
- All side effects from prior cancer treatments (except hair loss) have resolved to Grade 1 or baseline levels before joining the study
You will not qualify if you...
- Pregnant or breastfeeding females, or individuals unwilling to use contraception
- Known lymphoma involvement in the brain or central nervous system
- Active cancer within 2 years before joining the study
- Radiation or surgery for lymphoma within 2 weeks before first study drug dose without other disease sites
- Recent systemic cancer treatments, antibody therapies, or investigational agents within 4 weeks or less depending on half-life
- Uncontrolled illnesses
- Immunocompromised with recent opportunistic infections
- Active or chronic hepatitis B or active hepatitis C infection
- Received live vaccine within 30 days before or during the study
- Corrected QT interval over 470 milliseconds on ECG at screening
- Received COVID-19 vaccine within 3 weeks before study drug dosing
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 15 locations
1
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
Actively Recruiting
2
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
Actively Recruiting
3
Memorial Sloan Kettering
New York, New York, United States, 10065
Actively Recruiting
4
Hôpital Saint-Louis
Paris, Paris, France, 75610
Actively Recruiting
5
The Centre Léon Bérard
Lyon, France
Actively Recruiting
6
Institut Paoli Calmettes
Marseille, France
Actively Recruiting
7
CHU de Nantes
Nantes, France
Actively Recruiting
8
Institut Gustave Roussy
Villejuif, France
Actively Recruiting
9
University Hospitals of Leicester NHS Trust
Leicester, United Kingdom
Actively Recruiting
10
Imperial College / Clinical Trials Unit, Hammersmith Hospital
London, United Kingdom
Actively Recruiting
11
The Christie
Manchester, United Kingdom
Actively Recruiting
12
Nottingham City Hospital
Nottingham, United Kingdom
Actively Recruiting
13
Churchill Hospital
Oxford, United Kingdom
Actively Recruiting
14
Derriford Hospital
Plymouth, United Kingdom
Actively Recruiting
15
The Royal Marsden
Sutton, United Kingdom
Actively Recruiting
Research Team
M
Maureen Higgins
CONTACT
D
Duc Tran
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here